SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.

about

SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.

Item

http://www.wikidata.org/entity/Q54344733

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

SNPs in the transforming growt ...... ations treated with gefitinib.

@en

SNPs in the transforming growt ...... ations treated with gefitinib.

@nl

type

Item

label

SNPs in the transforming growt ...... ations treated with gefitinib.

@en

SNPs in the transforming growt ...... ations treated with gefitinib.

@nl

prefLabel

SNPs in the transforming growt ...... ations treated with gefitinib.

@en

SNPs in the transforming growt ...... ations treated with gefitinib.

@nl

P1476

SNPs in the transforming growt ...... tations treated with gefitinib

@en

P2093

H L Wu

http://www.w3.org/2001/XMLSchema#string

L Zhang

http://www.w3.org/2001/XMLSchema#string

M Yang

http://www.w3.org/2001/XMLSchema#string

Q X Li

http://www.w3.org/2001/XMLSchema#string

S Y Yu

http://www.w3.org/2001/XMLSchema#string

X Lu

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Non-Smad pathways in TGF-beta signaling

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Receptor type protein tyrosine phosphatase-kappa mediates cross-talk between transforming growth factor-beta and epidermal growth factor receptor signaling pathways in human keratinocytes

TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer

SNPs in the TGF-β signaling pathway are associated with increased risk of brain metastasis in patients with non-small-cell lung cancer

P304

1584-1590

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDU172

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

X Yuan

P577

2014-06-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263096897

http://www.w3.org/2001/XMLSchema#string

P698

24928833

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma